{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:56:59Z","timestamp":1782212219617,"version":"3.54.5"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatic adenomas (HAs) are relatively common benign liver tumors that carry small risks of hemorrhage and malignant transformation, both of which increase with tumor size. While traditionally linked to estrogen-containing oral contraceptives (OCPs), other risk factors including obesity have been associated with HA formation and growth. Treatment strategies depend on the risk of malignant transformation or hemorrhage, tumor size, histological subtype, and patient-specific factors. While traditionally, surgical resection has been the standard recommendation for large, symptomatic, or high-risk tumors, several non-operative strategies are now available to minimize morbidity and optimize outcomes. Active surveillance is recommended for patients with small (&lt;\u20095\u00a0cm), asymptomatic HAs without other risk factors. Loco-regional therapies, including transarterial embolization and radiofrequency ablation, have been used effectively, particularly for small tumors. Mounting evidence suggests that interventions aimed at weight loss, either through lifestyle modifications or bariatric surgery, are efficacious in reducing HA size. Recent data support expanding non-operative management for even large tumors (&gt;\u20095\u00a0cm), as they can respond to lifestyle interventions. Several subgroups of patients warrant special consideration, such as pregnant patients, males, and patients with hepatic adenomatosis. A personalized, multidisciplinary approach remains essential as non-operative strategies continue to expand along with emerging targeted therapies.<\/jats:p>","DOI":"10.1007\/s12029-026-01406-0","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T02:16:14Z","timestamp":1770948974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nonoperative Management of Hepatic Adenomas: A Review"],"prefix":"10.1007","volume":"57","author":[{"given":"Ian C.","family":"Garbarine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Cloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"3","key":"1406_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/13651820510028954","volume":"7","author":"L Barthelmes","year":"2005","unstructured":"Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford). 2005;7(3):186\u201396. https:\/\/doi.org\/10.1080\/13651820510028954.","journal-title":"HPB (Oxford)"},{"issue":"7","key":"1406_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1001\/jama.1979.03300070040020","volume":"242","author":"JB Rooks","year":"1979","unstructured":"Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979;242(7):644\u20138.","journal-title":"JAMA"},{"issue":"7835","key":"1406_CR3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/s0140-6736(73)92594-4","volume":"2","author":"JK Baum","year":"1973","unstructured":"Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973;2(7835):926\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(73)92594-4.","journal-title":"Lancet"},{"issue":"7","key":"1406_CR4","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/liv.13423","volume":"37","author":"L Bossen","year":"2017","unstructured":"Bossen L, Gr\u00f8nbaek H, Lykke Eriksen P, Jepsen P. Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: a nationwide population-based study. Liver Int. 2017;37(7):1042\u20136. https:\/\/doi.org\/10.1111\/liv.13423.","journal-title":"Liver Int"},{"key":"1406_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/604860","volume":"2013","author":"CY Chang","year":"2013","unstructured":"Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, Thung SN. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol. 2013;2013:604860. https:\/\/doi.org\/10.1155\/2013\/604860.","journal-title":"Int J Hepatol"},{"issue":"6","key":"1406_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/his.14605","volume":"80","author":"P Bioulac-Sage","year":"2022","unstructured":"Bioulac-Sage P, Gouw ASH, Balabaud C, Sempoux C. Hepatocellular adenoma: what we know, what we do not know, and why it matters. Histopathology. 2022;80(6):878\u201397. https:\/\/doi.org\/10.1111\/his.14605.","journal-title":"Histopathology"},{"issue":"8","key":"1406_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.1478-3231.2012.02786.x","volume":"32","author":"P Bioulac-Sage","year":"2012","unstructured":"Bioulac-Sage P, Taouji S, Possenti L, Balabaud C. Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver Int. 2012;32(8):1217\u201321. https:\/\/doi.org\/10.1111\/j.1478-3231.2012.02786.x.","journal-title":"Liver Int"},{"issue":"1","key":"1406_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/modpathol.2015.119","volume":"29","author":"J Calderaro","year":"2016","unstructured":"Calderaro J, Nault JC, Balabaud C, Couchy G, Saint-Paul MC, Azoulay D, et al. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. Mod Pathol. 2016;29(1):43\u201350. https:\/\/doi.org\/10.1038\/modpathol.2015.119.","journal-title":"Mod Pathol"},{"issue":"5","key":"1406_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1053\/j.gastro.2013.02.032","volume":"144","author":"JC Nault","year":"2013","unstructured":"Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology. 2013;144(5):888\u2013902. https:\/\/doi.org\/10.1053\/j.gastro.2013.02.032.","journal-title":"Gastroenterology"},{"issue":"9","key":"1406_CR10","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1177\/00031348211011084","volume":"88","author":"TS Silva","year":"2022","unstructured":"Silva TS, Sung M, Nelson DW, DiFronzo AL, O\u2019Connor VV. A multicenter, 10-year experience with hepatocellular adenoma: risk factors and disease course. Am Surg. 2022;88(9):2345\u201350. https:\/\/doi.org\/10.1177\/00031348211011084.","journal-title":"Am Surg"},{"issue":"6","key":"1406_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1002\/jmri.26902","volume":"51","author":"M Zulfiqar","year":"2020","unstructured":"Zulfiqar M, Sirlin CB, Yoneda N, Ronot M, Hecht EM, Chernyak V, et al. Hepatocellular adenomas: understanding the pathomolecular lexicon, MRI features, terminology, and pitfalls to inform a standardized approach. J Magn Reson Imaging. 2020;51(6):1630\u201340. https:\/\/doi.org\/10.1002\/jmri.26902.","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"1406_CR12","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1053\/j.gastro.2016.11.042","volume":"152","author":"JC Nault","year":"2017","unstructured":"Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, et al. Molecular classification of hepatocellular adenoma associates with risk Factors, Bleeding, and malignant transformation. Gastroenterology. 2017;152(4):880\u2013e946. https:\/\/doi.org\/10.1053\/j.gastro.2016.11.042.","journal-title":"Gastroenterology"},{"issue":"3","key":"1406_CR13","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220134","volume":"43","author":"JR Tse","year":"2023","unstructured":"Tse JR, Felker ER, Naini BV, Shen L, Shen J, Lu DSK, et al. Hepatocellular adenomas: molecular basis and multimodality imaging update. Radiographics. 2023;43(3):e220134. https:\/\/doi.org\/10.1148\/rg.220134.","journal-title":"Radiographics"},{"issue":"1","key":"1406_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.clinre.2018.07.007","volume":"43","author":"P Bioulac-Sage","year":"2019","unstructured":"Bioulac-Sage P, Sempoux C, Frulio N, Le Bail B, Blanc JF, Castain C, et al. Snapshot summary of diagnosis and management of hepatocellular adenoma subtypes. Clin Res Hepatol Gastroenterol. 2019;43(1):12\u20139. https:\/\/doi.org\/10.1016\/j.clinre.2018.07.007.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"10","key":"1406_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.4254\/wjh.v7.i10.1403","volume":"7","author":"AK de Koehne Gonzalez","year":"2015","unstructured":"Koehne de Gonzalez AK, Salomao MA, Lagana SM. Current concepts in the immunohistochemical evaluation of liver tumors. World J Hepatol. 2015;7(10):1403\u201311. https:\/\/doi.org\/10.4254\/wjh.v7.i10.1403.","journal-title":"World J Hepatol"},{"issue":"2","key":"1406_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100913","volume":"6","author":"S Di Tommaso","year":"2024","unstructured":"Di Tommaso S, Dourthe C, Dupuy JW, Dugot-Senant N, Cappellen D, Cazier H, et al. Spatial characterisation of \u03b2-catenin-mutated hepatocellular adenoma subtypes by proteomic profiling of the tumour rim. JHEP Rep. 2024;6(2):100913. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100913.","journal-title":"JHEP Rep"},{"issue":"6","key":"1406_CR17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.gassur.2024.03.010","volume":"28","author":"H Aziz","year":"2024","unstructured":"Aziz H, Underwood PW, Gosse MD, Afyouni S, Kamel I, Pawlik TM. Hepatic adenoma: evolution of a more individualized treatment approach. J Gastrointest Surg. 2024;28(6):975\u201382. https:\/\/doi.org\/10.1016\/j.gassur.2024.03.010.","journal-title":"J Gastrointest Surg"},{"issue":"9","key":"1406_CR18","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1245\/s10434-020-08580-w","volume":"27","author":"K Krause","year":"2020","unstructured":"Krause K, Tanabe KK. A shifting paradigm in diagnosis and management of hepatic adenoma. Ann Surg Oncol. 2020;27(9):3330\u20138. https:\/\/doi.org\/10.1245\/s10434-020-08580-w.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1406_CR19","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1053\/j.gastro.2009.07.061","volume":"137","author":"S Dokmak","year":"2009","unstructured":"Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137(5):1698\u2013705. https:\/\/doi.org\/10.1053\/j.gastro.2009.07.061.","journal-title":"Gastroenterology"},{"issue":"7","key":"1406_CR20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.14309\/ajg.0000000000002857","volume":"119","author":"C Frenette","year":"2024","unstructured":"Frenette C, Mendiratta-Lala M, Salgia R, Wong RJ, Sauer BG, Pillai A. ACG clinical guideline: focal liver lesions. Am J Gastroenterol. 2024;119(7):1235\u201371. https:\/\/doi.org\/10.14309\/ajg.0000000000002857.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1406_CR21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/sla.0000000000003043","volume":"271","author":"JM Cloyd","year":"2020","unstructured":"Cloyd JM, Mizuno T, Kawaguchi Y, Lillemoe HA, Karagkounis G, Omichi K, et al. Comprehensive complication index validates improved outcomes over time despite increased complexity in 3707 consecutive hepatectomies. Ann Surg. 2020;271(4):724\u201331. https:\/\/doi.org\/10.1097\/sla.0000000000003043.","journal-title":"Ann Surg"},{"issue":"6","key":"1406_CR22","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.surg.2021.06.028","volume":"170","author":"JD Beane","year":"2021","unstructured":"Beane JD, Hyer M, Mehta R, Onuma AE, Gleeson EM, Thompson VM, et al. Optimal hepatic surgery: are we making progress in North America? Surgery. 2021;170(6):1741\u20138. https:\/\/doi.org\/10.1016\/j.surg.2021.06.028.","journal-title":"Surgery"},{"issue":"7","key":"1406_CR23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.ejso.2020.03.227","volume":"46","author":"P Gavriilidis","year":"2020","unstructured":"Gavriilidis P, Roberts KJ, Aldrighetti L, Sutcliffe RP. A comparison between robotic, laparoscopic and open hepatectomy: a systematic review and network meta-analysis. Eur J Surg Oncol. 2020;46(7):1214\u201324. https:\/\/doi.org\/10.1016\/j.ejso.2020.03.227.","journal-title":"Eur J Surg Oncol"},{"issue":"10019","key":"1406_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/s0140-6736(15)00803-x","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(15)00803-x.","journal-title":"Lancet"},{"issue":"2","key":"1406_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jhep.2016.04.001","volume":"65","author":"EASL Clinical Practice Guidelines on the management of benign liver tumours","year":"2016","unstructured":"EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol. 2016;65(2):386\u201398. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.001.","journal-title":"J Hepatol"},{"issue":"6","key":"1406_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1530\/eje-07-0020","volume":"156","author":"M Svrcek","year":"2007","unstructured":"Svrcek M, Jeannot E, Arriv\u00e9 L, Poupon R, Fromont G, Fl\u00e9jou JF, et al. Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. Eur J Endocrinol. 2007;156(6):617\u201321. https:\/\/doi.org\/10.1530\/eje-07-0020.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1406_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/hep.29151","volume":"66","author":"M Sinclair","year":"2017","unstructured":"Sinclair M, Schelleman A, Sandhu D, Angus PW. Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy. Hepatology. 2017;66(3):989\u201391. https:\/\/doi.org\/10.1002\/hep.29151.","journal-title":"Hepatology"},{"issue":"12","key":"1406_CR28","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/bjs.10594","volume":"104","author":"AJ Klompenhouwer","year":"2017","unstructured":"Klompenhouwer AJ, Br\u00f6ker MEE, Thomeer MGJ, Gaspersz MP, de Man RA, JNM IJ. Retrospective study on timing of resection of hepatocellular adenoma. Br J Surg. 2017;104(12):1695\u2013703. https:\/\/doi.org\/10.1002\/bjs.10594.","journal-title":"Br J Surg"},{"issue":"5","key":"1406_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/liv.14074","volume":"39","author":"MPD Haring","year":"2019","unstructured":"Haring MPD, Gouw ASH, de Haas RJ, Cuperus FJC, de Jong KP, de Meijer VE. The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: a retrospective cohort study. Liver Int. 2019;39(5):905\u201313. https:\/\/doi.org\/10.1111\/liv.14074.","journal-title":"Liver Int"},{"issue":"3","key":"1406_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.51821\/84.3.017","volume":"84","author":"G Moors","year":"2021","unstructured":"Moors G, Poels H, Vandecaveye V, Roskams T, Verslype C. Regression of multiple hepatocellular adenomas after cessation of oral contraceptive pills: a case report and review of the current literature. Acta Gastroenterol Belg. 2021;84(3):505\u20138. https:\/\/doi.org\/10.51821\/84.3.017.","journal-title":"Acta Gastroenterol Belg"},{"key":"1406_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/8904_2014_344","volume":"18","author":"RD Beegle","year":"2015","unstructured":"Beegle RD, Brown LM, Weinstein DA. Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I. JIMD Rep. 2015;18:23\u201332. https:\/\/doi.org\/10.1007\/8904_2014_344.","journal-title":"JIMD Rep"},{"issue":"10","key":"1406_CR32","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1111\/liv.12925","volume":"35","author":"S Dokmak","year":"2015","unstructured":"Dokmak S, Belghiti J. Will weight loss become a future treatment of hepatocellular adenoma in obese patients? Liver Int. 2015;35(10):2228\u201332. https:\/\/doi.org\/10.1111\/liv.12925.","journal-title":"Liver Int"},{"issue":"4","key":"1406_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metab"},{"issue":"2","key":"1406_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"issue":"6","key":"1406_CR35","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","volume":"39","author":"M Jensterle","year":"2022","unstructured":"Jensterle M, Rizzo M, Haluz\u00edk M, Jane\u017e A. Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review. Adv Ther. 2022;39(6):2452\u201367. https:\/\/doi.org\/10.1007\/s12325-022-02153-x.","journal-title":"Adv Ther"},{"issue":"12","key":"1406_CR36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1467-789X.2010.00740.x","volume":"11","author":"JC Barte","year":"2010","unstructured":"Barte JC, ter Bogt NC, Bogers RP, Teixeira PJ, Blissmer B, Mori TA, et al. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obes Rev. 2010;11(12):899\u2013906. https:\/\/doi.org\/10.1111\/j.1467-789X.2010.00740.x.","journal-title":"Obes Rev"},{"issue":"1","key":"1406_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11695-020-04889-3","volume":"31","author":"V Mocanu","year":"2021","unstructured":"Mocanu V, Mihajlovic I, Dang JT, Birch DW, Karmali S, Switzer NJ. Evolving trends in North American gastric bypass delivery: a retrospective MBSAQIP analysis of technical factors and outcomes from 2015 to 2018. Obes Surg. 2021;31(1):151\u20138. https:\/\/doi.org\/10.1007\/s11695-020-04889-3.","journal-title":"Obes Surg"},{"issue":"12","key":"1406_CR38","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1111\/liv.13934","volume":"38","author":"TJG Gevers","year":"2018","unstructured":"Gevers TJG, Marcel Spanier BW, Veendrick PB, Vrolijk JM. Regression of hepatocellular adenoma after bariatric surgery in severe obese patients. Liver Int. 2018;38(12):2134\u20136. https:\/\/doi.org\/10.1111\/liv.13934.","journal-title":"Liver Int"},{"issue":"12","key":"1406_CR39","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.soard.2020.06.043","volume":"16","author":"J Goonawardena","year":"2020","unstructured":"Goonawardena J, Ratnayake C, Cheung KT, Fox A. Should bariatric surgery be offered for hepatocellular adenomas in obese patients? Surg Obes Relat Dis. 2020;16(12):2117\u201324. https:\/\/doi.org\/10.1016\/j.soard.2020.06.043.","journal-title":"Surg Obes Relat Dis"},{"key":"1406_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-025-12350-8","author":"IC Garbarine","year":"2025","unstructured":"Garbarine IC, Walsh AK, Pawlik TM, Noria SF, Cloyd JM. Hepatic adenoma regression after bariatric surgery: a case series and systematic review. Surg Endosc. 2025. https:\/\/doi.org\/10.1007\/s00464-025-12350-8.","journal-title":"Surg Endosc"},{"issue":"1","key":"1406_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000268427","volume":"27","author":"VA Huurman","year":"2010","unstructured":"Huurman VA, Schaapherder AF. Management of ruptured hepatocellular adenoma. Dig Surg. 2010;27(1):56\u201360. https:\/\/doi.org\/10.1159\/000268427.","journal-title":"Dig Surg"},{"issue":"7","key":"1406_CR42","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/bjs.10547","volume":"104","author":"BV van Rosmalen","year":"2017","unstructured":"van Rosmalen BV, Coelen RJS, Bieze M, van Delden OM, Verheij J, Dejong CHC, et al. Systematic review of transarterial embolization for hepatocellular adenomas. Br J Surg. 2017;104(7):823\u201335. https:\/\/doi.org\/10.1002\/bjs.10547.","journal-title":"Br J Surg"},{"issue":"2","key":"1406_CR43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jvir.2015.09.021","volume":"27","author":"AR Smolock","year":"2016","unstructured":"Smolock AR, Cristescu MM, Potretzke TA, Ziemlewicz TJ, Lubner MG, Hinshaw JL, et al. Microwave ablation for the treatment of hepatic adenomas. J Vasc Interv Radiol. 2016;27(2):244\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2015.09.021.","journal-title":"J Vasc Interv Radiol"},{"key":"1406_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230x-12-82","volume":"12","author":"SM van Aalten","year":"2012","unstructured":"van Aalten SM, Br\u00f6ker ME, Busschbach JJ, de Koning HJ, de Man RA, Steegers EA, et al. Pregnancy and liver adenoma management: PALM-study. BMC Gastroenterol. 2012;12:82. https:\/\/doi.org\/10.1186\/1471-230x-12-82.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"1406_CR45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jhep.2010.07.022","volume":"54","author":"JE Noels","year":"2011","unstructured":"Noels JE, van Aalten SM, van der Windt DJ, Kok NF, de Man RA, Terkivatan T, et al. Management of hepatocellular adenoma during pregnancy. J Hepatol. 2011;54(3):553\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2010.07.022.","journal-title":"J Hepatol"},{"issue":"10","key":"1406_CR46","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/bjs.11213","volume":"106","author":"BV van Rosmalen","year":"2019","unstructured":"van Rosmalen BV, Klompenhouwer AJ, de Graeff JJ, Haring MPD, de Meijer VE, Rifai L, et al. Safety and efficacy of transarterial embolization of hepatocellular adenomas. Br J Surg. 2019;106(10):1362\u201371. https:\/\/doi.org\/10.1002\/bjs.11213.","journal-title":"Br J Surg"},{"issue":"5","key":"1406_CR47","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00270-003-2758-y","volume":"27","author":"SH Lee","year":"2004","unstructured":"Lee SH, Hahn ST. Treatment of multiple hepatic adenomatosis using transarterial chemoembolization: a case report. Cardiovasc Intervent Radiol. 2004;27(5):563\u20135. https:\/\/doi.org\/10.1007\/s00270-003-2758-y.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"1406_CR48","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jvir.2007.04.014","volume":"18","author":"YI Kim","year":"2007","unstructured":"Kim YI, Chung JW, Park JH. Feasibility of transcatheter arterial chemoembolization for hepatic adenoma. J Vasc Interv Radiol. 2007;18(7):862\u20137. https:\/\/doi.org\/10.1016\/j.jvir.2007.04.014.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"1406_CR49","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jvir.2011.02.027","volume":"22","author":"A Deodhar","year":"2011","unstructured":"Deodhar A, Brody LA, Covey AM, Brown KT, Getrajdman GI. Bland embolization in the treatment of hepatic adenomas: preliminary experience. J Vasc Interv Radiol. 2011;22(6):795\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2011.02.027.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"1406_CR50","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/jso.21933","volume":"104","author":"KA Simo","year":"2011","unstructured":"Simo KA, Sereika SE, Newton KN, Gerber DA. Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: safety and efficacy in comparison with radiofrequency ablation. J Surg Oncol. 2011;104(7):822\u20139. https:\/\/doi.org\/10.1002\/jso.21933.","journal-title":"J Surg Oncol"},{"issue":"3","key":"1406_CR51","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12029-020-00477-x","volume":"52","author":"MM Mogahed","year":"2021","unstructured":"Mogahed MM, Zytoon AA, Eysa B, Manaa M, Abdellatif W. Outcome of laparoscopic assisted percutaneous microwave ablation for exophytic versus non-exophytic hepatocellular carcinoma. J Gastrointest Cancer. 2021;52(3):892\u20138. https:\/\/doi.org\/10.1007\/s12029-020-00477-x.","journal-title":"J Gastrointest Cancer"},{"issue":"6","key":"1406_CR52","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jvir.2011.02.024","volume":"22","author":"MG van Vledder","year":"2011","unstructured":"van Vledder MG, van Aalten SM, Terkivatan T, de Man RA, Leertouwer T, Ijzermans JN. Safety and efficacy of radiofrequency ablation for hepatocellular adenoma. J Vasc Interv Radiol. 2011;22(6):787\u201393. https:\/\/doi.org\/10.1016\/j.jvir.2011.02.024.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"1406_CR53","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00270-018-1893-4","volume":"41","author":"O Mironov","year":"2018","unstructured":"Mironov O, Jaberi A, Beecroft R, Kachura JR. Retrospective single-arm cohort study of patients with hepatocellular adenomas treated with percutaneous thermal ablation. Cardiovasc Intervent Radiol. 2018;41(6):935\u201341. https:\/\/doi.org\/10.1007\/s00270-018-1893-4.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"1406_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jhep.2019.09.011","volume":"72","author":"MP Gaspersz","year":"2020","unstructured":"Gaspersz MP, Klompenhouwer AJ, Broker MEE, Thomeer MGJ, van Aalten SM, Steegers E, et al. Growth of hepatocellular adenoma during pregnancy: a prospective study. J Hepatol. 2020;72(1):119\u201324. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.011.","journal-title":"J Hepatol"},{"issue":"8","key":"1406_CR55","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.hpb.2021.04.019","volume":"23","author":"MPD Haring","year":"2021","unstructured":"Haring MPD, Spijkerboer CS, Cuperus FJC, Duiker EW, de Jong KP, de Haas RJ, et al. Behavior and complications of hepatocellular adenoma during pregnancy and puerperium: a retrospective study and systematic review. HPB (Oxford). 2021;23(8):1152\u201363. https:\/\/doi.org\/10.1016\/j.hpb.2021.04.019.","journal-title":"HPB (Oxford)"},{"issue":"1","key":"1406_CR56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11605-018-3917-4","volume":"23","author":"DI Tsilimigras","year":"2019","unstructured":"Tsilimigras DI, Rahnemai-Azar AA, Ntanasis-Stathopoulos I, Gavriatopoulou M, Moris D, Spartalis E, et al. Current approaches in the management of hepatic adenomas. J Gastrointest Surg. 2019;23(1):199\u2013209. https:\/\/doi.org\/10.1007\/s11605-018-3917-4.","journal-title":"J Gastrointest Surg"},{"key":"1406_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/725735","volume":"2012","author":"ME Br\u00f6ker","year":"2012","unstructured":"Br\u00f6ker ME, Ijzermans JN, van Aalten SM, de Man RA, Terkivatan T. The management of pregnancy in women with hepatocellular adenoma: a plea for an individualized approach. Int J Hepatol. 2012;2012:725735. https:\/\/doi.org\/10.1155\/2012\/725735.","journal-title":"Int J Hepatol"},{"issue":"1","key":"1406_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13651820310020846","volume":"6","author":"M Ronald","year":"2004","unstructured":"Ronald M, Woodfield J, McCall J, Koea J. Hepatic adenomas in male patients. HPB (Oxford). 2004;6(1):25\u20137. https:\/\/doi.org\/10.1080\/13651820310020846.","journal-title":"HPB (Oxford)"},{"key":"1406_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105795","volume":"159","author":"E Jain","year":"2025","unstructured":"Jain E, Anderson SA, Ollila E, Johnson DB, Chandrashekar DS, Osme A, et al. Hepatic adenomas in males: is molecular characterization helpful in guiding its management? Hum Pathol. 2025;159:105795. https:\/\/doi.org\/10.1016\/j.humpath.2025.105795.","journal-title":"Hum Pathol"},{"issue":"10","key":"1406_CR60","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1111\/liv.14989","volume":"41","author":"BV van Rosmalen","year":"2021","unstructured":"van Rosmalen BV, Furumaya A, Klompenhouwer AJ, Tushuizen ME, Braat AE, Reinten RJ, et al. Hepatocellular adenoma in men: a nationwide assessment of pathology and correlation with clinical course. Liver Int. 2021;41(10):2474\u201384. https:\/\/doi.org\/10.1111\/liv.14989.","journal-title":"Liver Int"},{"key":"1406_CR61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.humpath.2023.05.010","volume":"138","author":"IA Gonz\u00e1lez","year":"2023","unstructured":"Gonz\u00e1lez IA, Torbenson M, Sharifai N, Byrnes K, Chatterjee D, Kakar S, et al. Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience. Hum Pathol. 2023;138:24\u201333. https:\/\/doi.org\/10.1016\/j.humpath.2023.05.010.","journal-title":"Hum Pathol"},{"key":"1406_CR62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.humpath.2024.05.003","volume":"149","author":"C Sempoux","year":"2023","unstructured":"Sempoux C, Balabaud C, Gouw AS, Bioulac-Sage P. Letter to the editor there are benefits of subtyping hepatocellular adenoma also in men. Following-up on the publication by Gonz\u00e1lez IA et al. Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience. Hum Pathol. 2023;149:77\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2024.05.003.","journal-title":"Hum Pathol"},{"issue":"10","key":"1406_CR63","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1111\/liv.15050","volume":"41","author":"E Mauro","year":"2021","unstructured":"Mauro E, Forner A. Hepatocellular adenoma in men: is it time for a precision approach? Liver Int. 2021;41(10):2246\u20138. https:\/\/doi.org\/10.1111\/liv.15050.","journal-title":"Liver Int"},{"issue":"2","key":"1406_CR64","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11901-015-0265-7","volume":"14","author":"C Meyer","year":"2015","unstructured":"Meyer C, Lisker-Melman M. Treatment of hepatic adenomatosis. Curr Hepatol Rep. 2015;14(2):139\u201343. https:\/\/doi.org\/10.1007\/s11901-015-0265-7.","journal-title":"Curr Hepatol Rep"},{"issue":"2","key":"1406_CR65","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.22995","volume":"50","author":"P Bioulac-Sage","year":"2009","unstructured":"Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50(2):481\u20139. https:\/\/doi.org\/10.1002\/hep.22995.","journal-title":"Hepatology"},{"issue":"6","key":"1406_CR66","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jhep.2019.08.004","volume":"71","author":"L Barbier","year":"2019","unstructured":"Barbier L, Nault JC, Dujardin F, Scotto B, Besson M, de Muret A, et al. Natural history of liver adenomatosis: a long-term observational study. J Hepatol. 2019;71(6):1184\u201392. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.004.","journal-title":"J Hepatol"},{"issue":"4","key":"1406_CR67","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1590\/s1679-45082013000400021","volume":"11","author":"F Nasser","year":"2013","unstructured":"Nasser F, Affonso BB, Galastri FL, Odisio BC, Garcia RG. Minimally invasive treatment of hepatic adenoma in special cases. Einstein (Sao Paulo). 2013;11(4):524\u20137. https:\/\/doi.org\/10.1590\/s1679-45082013000400021.","journal-title":"Einstein (Sao Paulo)"},{"issue":"12","key":"1406_CR68","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27090","volume":"2","author":"K Poussin","year":"2013","unstructured":"Poussin K, Pilati C, Couchy G, Calderaro J, Bioulac-Sage P, Bacq Y, et al. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology. 2013;2(12):e27090. https:\/\/doi.org\/10.4161\/onci.27090.","journal-title":"Oncoimmunology"},{"issue":"17","key":"1406_CR69","doi-asserted-by":"publisher","first-page":"13743","DOI":"10.1074\/jbc.M111.349167","volume":"287","author":"J Sommer","year":"2012","unstructured":"Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J, et al. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes Interleukin 11 signaling. J Biol Chem. 2012;287(17):13743\u201351. https:\/\/doi.org\/10.1074\/jbc.M111.349167.","journal-title":"J Biol Chem"},{"issue":"23","key":"1406_CR70","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1200\/jco.2009.27.2377","volume":"28","author":"F van Rhee","year":"2010","unstructured":"van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman\u2019s disease. J Clin Oncol. 2010;28(23):3701\u20138. https:\/\/doi.org\/10.1200\/jco.2009.27.2377.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1406_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104088","volume":"10","author":"JY Blay","year":"2025","unstructured":"Blay JY, Brahmi M, Dufresne A, Swalduz A, Avrillon V, Assaad S, et al. Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers. ESMO Open. 2025;10(1):104088. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104088.","journal-title":"ESMO Open"},{"issue":"4","key":"1406_CR72","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.03.005","volume":"25","author":"C Pilati","year":"2014","unstructured":"Pilati C, Letouz\u00e9 E, Nault JC, Imbeaud S, Boulai A, Calderaro J, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25(4):428\u201341. https:\/\/doi.org\/10.1016\/j.ccr.2014.03.005.","journal-title":"Cancer Cell"},{"key":"1406_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093126","author":"K Harada","year":"2020","unstructured":"Harada K, Ohashi R, Naito K, Kanki K. Hedgehog signal inhibitor GANT61 inhibits the malignant behavior of undifferentiated hepatocellular carcinoma cells by targeting non-canonical GLI signaling. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21093126.","journal-title":"Int J Mol Sci"},{"key":"1406_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106858","volume":"195","author":"L Maresca","year":"2023","unstructured":"Maresca L, Crivaro E, Migliorini F, Anichini G, Giammona A, Pepe S, et al. Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth. Pharmacol Res. 2023;195:106858. https:\/\/doi.org\/10.1016\/j.phrs.2023.106858.","journal-title":"Pharmacol Res"},{"issue":"16","key":"1406_CR75","doi-asserted-by":"publisher","first-page":"16154","DOI":"10.1074\/jbc.M400346200","volume":"279","author":"P Gervois","year":"2004","unstructured":"Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, et al. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem. 2004;279(16):16154\u201360. https:\/\/doi.org\/10.1074\/jbc.M400346200.","journal-title":"J Biol Chem"},{"issue":"1","key":"1406_CR76","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clinre.2015.09.009","volume":"40","author":"R Poupon","year":"2016","unstructured":"Poupon R, Cazals-Hatem D, Arriv\u00e9 L. Fenofibrate-induced massive regression of mutiple inflammatory hepatocellular adenoma. Clin Res Hepatol Gastroenterol. 2016;40(1):e1\u20133. https:\/\/doi.org\/10.1016\/j.clinre.2015.09.009.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1406_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165722","author":"M Kojima","year":"2020","unstructured":"Kojima M, Takahashi H, Kuwashiro T, Tanaka K, Mori H, Ozaki I, et al. Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21165722.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1406_CR78","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.3892\/mmr.2019.10750","volume":"20","author":"H Wang","year":"2019","unstructured":"Wang H, Feng X, Han P, Lei Y, Xia Y, Tian D, et al. The JAK inhibitor tofacitinib ameliorates immune\u2011mediated liver injury in mice. Mol Med Rep. 2019;20(6):4883\u201392. https:\/\/doi.org\/10.3892\/mmr.2019.10750.","journal-title":"Mol Med Rep"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01406-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T02:16:15Z","timestamp":1770948975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01406-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01406-0","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"27 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"43"}}